AAPL344.66+5.16 (+1.52%) ▲|ABBV283.42-5.66 (-1.96%) ▼|ABT98.83-3.63 (-3.54%) ▼|ACN240.08+0.96 (+0.40%) ▲|ADBE255.87-0.86 (-0.34%) ▼|AMAT411.29+6.31 (+1.56%) ▲|AMD550.08+15.34 (+2.87%) ▲|AMGN435.60-3.34 (-0.76%) ▼|AMT179.03-4.53 (-2.47%) ▼|AMZN262.64+0.01 (+0.00%) ▲|AVGO337.09+2.72 (+0.81%) ▲|AXP323.91+5.57 (+1.75%) ▲|BA191.62+1.15 (+0.60%) ▲|BAC51.01+0.37 (+0.72%) ▲|BKNG157.98-5.94 (-3.62%) ▼|BLK1,136.54+7.86 (+0.70%) ▲|BMY60.84-0.85 (-1.37%) ▼|BNY146.34+2.09 (+1.45%) ▲|BRK-B542.91+3.09 (+0.57%) ▲|C123.25+0.74 (+0.60%) ▲|CAT736.22+10.98 (+1.51%) ▲|CL93.68-0.86 (-0.91%) ▼|CMCSA21.87-0.50 (-2.21%) ▼|COF209.61+8.05 (+3.99%) ▲|COP145.84-0.12 (-0.08%) ▼|COST995.37+0.76 (+0.08%) ▲|CRM242.91+0.48 (+0.20%) ▲|CSCO106.85+0.14 (+0.13%) ▲|CVS94.29-0.46 (-0.49%) ▼|CVX226.33+0.62 (+0.27%) ▲|DE631.14-1.07 (-0.17%) ▼|DHR232.70+8.46 (+3.77%) ▲|DIS110.84-0.83 (-0.74%) ▼|DUK121.43+0.10 (+0.08%) ▲|EMR163.27+2.81 (+1.75%) ▲|FDX298.99+0.23 (+0.08%) ▲|GD346.42+1.98 (+0.57%) ▲|GE300.83+0.96 (+0.32%) ▲|GEV928.69+38.36 (+4.31%) ▲|GILD152.93-3.59 (-2.29%) ▼|GM75.75-1.34 (-1.74%) ▼|GOOG328.98-7.42 (-2.21%) ▼|GOOGL332.99-7.29 (-2.14%) ▼|GS899.26+14.45 (+1.63%) ▲|HD314.35-0.76 (-0.24%) ▼|HON213.59+0.27 (+0.13%) ▲|IBM244.06+2.14 (+0.88%) ▲|INTC92.55+0.86 (+0.93%) ▲|INTU334.65-0.64 (-0.19%) ▼|ISRG431.71-6.30 (-1.44%) ▼|JNJ255.95-3.42 (-1.32%) ▼|JPM333.71-1.55 (-0.46%) ▼|KO92.91-0.58 (-0.62%) ▼|LIN499.54-2.35 (-0.47%) ▼|LLY1,268.01-15.65 (-1.22%) ▼|LMT549.58+0.87 (+0.16%) ▲|LOW196.58-0.71 (-0.36%) ▼|LRCX266.80+3.35 (+1.27%) ▲|MA623.27+2.85 (+0.46%) ▲|MCD245.81-0.71 (-0.29%) ▼|MDLZ62.81-1.18 (-1.84%) ▼|MDT93.51-1.13 (-1.19%) ▼|META710.75+16.50 (+2.38%) ▲|MMM171.12-0.25 (-0.15%) ▼|MO73.94-0.70 (-0.94%) ▼|MRK148.69+0.39 (+0.26%) ▲|MS183.57+3.17 (+1.76%) ▲|MSFT531.69-0.18 (-0.03%) ▼|MU912.63+16.56 (+1.85%) ▲|NEE78.59-0.27 (-0.35%) ▼|NFLX65.26-3.43 (-4.99%) ▼|NKE37.49-0.39 (-1.03%) ▼|NOW153.29+3.75 (+2.51%) ▲|NVDA220.46+3.99 (+1.84%) ▲|ORCL130.08-1.06 (-0.81%) ▼|PEP135.12+1.10 (+0.82%) ▲|PFE29.77-0.34 (-1.13%) ▼|PG157.75-1.58 (-0.99%) ▼|PLTR199.53+6.93 (+3.60%) ▲|PM196.75-3.15 (-1.58%) ▼|QCOM178.26+2.55 (+1.45%) ▲|RTX191.12-2.22 (-1.15%) ▼|SBUX98.82-0.55 (-0.55%) ▼|SCHW91.92+1.03 (+1.13%) ▲|SO90.71+0.00 (+0.00%) ▲|SPG206.31-0.68 (-0.33%) ▼|T21.98-1.45 (-6.17%) ▼|TMO702.36+14.99 (+2.18%) ▲|TMUS153.32-4.44 (-2.81%) ▼|TSLA386.40+12.69 (+3.40%) ▲|TXN286.26+8.48 (+3.05%) ▲|UBER68.18-0.76 (-1.10%) ▼|UNH416.31-2.96 (-0.70%) ▼|UNP289.75+2.14 (+0.74%) ▲|UPS99.61+1.09 (+1.10%) ▲|USB59.31+0.22 (+0.36%) ▲|V409.27+2.70 (+0.66%) ▲|VZ43.41-1.14 (-2.55%) ▼|WFC82.43+0.23 (+0.28%) ▲|WMT118.01+0.16 (+0.13%) ▲|XOM177.68-0.18 (-0.10%) ▼|AAPL344.66+5.16 (+1.52%) ▲|ABBV283.42-5.66 (-1.96%) ▼|ABT98.83-3.63 (-3.54%) ▼|ACN240.08+0.96 (+0.40%) ▲|ADBE255.87-0.86 (-0.34%) ▼|AMAT411.29+6.31 (+1.56%) ▲|AMD550.08+15.34 (+2.87%) ▲|AMGN435.60-3.34 (-0.76%) ▼|AMT179.03-4.53 (-2.47%) ▼|AMZN262.64+0.01 (+0.00%) ▲|AVGO337.09+2.72 (+0.81%) ▲|AXP323.91+5.57 (+1.75%) ▲|BA191.62+1.15 (+0.60%) ▲|BAC51.01+0.37 (+0.72%) ▲|BKNG157.98-5.94 (-3.62%) ▼|BLK1,136.54+7.86 (+0.70%) ▲|BMY60.84-0.85 (-1.37%) ▼|BNY146.34+2.09 (+1.45%) ▲|BRK-B542.91+3.09 (+0.57%) ▲|C123.25+0.74 (+0.60%) ▲|CAT736.22+10.98 (+1.51%) ▲|CL93.68-0.86 (-0.91%) ▼|CMCSA21.87-0.50 (-2.21%) ▼|COF209.61+8.05 (+3.99%) ▲|COP145.84-0.12 (-0.08%) ▼|COST995.37+0.76 (+0.08%) ▲|CRM242.91+0.48 (+0.20%) ▲|CSCO106.85+0.14 (+0.13%) ▲|CVS94.29-0.46 (-0.49%) ▼|CVX226.33+0.62 (+0.27%) ▲|DE631.14-1.07 (-0.17%) ▼|DHR232.70+8.46 (+3.77%) ▲|DIS110.84-0.83 (-0.74%) ▼|DUK121.43+0.10 (+0.08%) ▲|EMR163.27+2.81 (+1.75%) ▲|FDX298.99+0.23 (+0.08%) ▲|GD346.42+1.98 (+0.57%) ▲|GE300.83+0.96 (+0.32%) ▲|GEV928.69+38.36 (+4.31%) ▲|GILD152.93-3.59 (-2.29%) ▼|GM75.75-1.34 (-1.74%) ▼|GOOG328.98-7.42 (-2.21%) ▼|GOOGL332.99-7.29 (-2.14%) ▼|GS899.26+14.45 (+1.63%) ▲|HD314.35-0.76 (-0.24%) ▼|HON213.59+0.27 (+0.13%) ▲|IBM244.06+2.14 (+0.88%) ▲|INTC92.55+0.86 (+0.93%) ▲|INTU334.65-0.64 (-0.19%) ▼|ISRG431.71-6.30 (-1.44%) ▼|JNJ255.95-3.42 (-1.32%) ▼|JPM333.71-1.55 (-0.46%) ▼|KO92.91-0.58 (-0.62%) ▼|LIN499.54-2.35 (-0.47%) ▼|LLY1,268.01-15.65 (-1.22%) ▼|LMT549.58+0.87 (+0.16%) ▲|LOW196.58-0.71 (-0.36%) ▼|LRCX266.80+3.35 (+1.27%) ▲|MA623.27+2.85 (+0.46%) ▲|MCD245.81-0.71 (-0.29%) ▼|MDLZ62.81-1.18 (-1.84%) ▼|MDT93.51-1.13 (-1.19%) ▼|META710.75+16.50 (+2.38%) ▲|MMM171.12-0.25 (-0.15%) ▼|MO73.94-0.70 (-0.94%) ▼|MRK148.69+0.39 (+0.26%) ▲|MS183.57+3.17 (+1.76%) ▲|MSFT531.69-0.18 (-0.03%) ▼|MU912.63+16.56 (+1.85%) ▲|NEE78.59-0.27 (-0.35%) ▼|NFLX65.26-3.43 (-4.99%) ▼|NKE37.49-0.39 (-1.03%) ▼|NOW153.29+3.75 (+2.51%) ▲|NVDA220.46+3.99 (+1.84%) ▲|ORCL130.08-1.06 (-0.81%) ▼|PEP135.12+1.10 (+0.82%) ▲|PFE29.77-0.34 (-1.13%) ▼|PG157.75-1.58 (-0.99%) ▼|PLTR199.53+6.93 (+3.60%) ▲|PM196.75-3.15 (-1.58%) ▼|QCOM178.26+2.55 (+1.45%) ▲|RTX191.12-2.22 (-1.15%) ▼|SBUX98.82-0.55 (-0.55%) ▼|SCHW91.92+1.03 (+1.13%) ▲|SO90.71+0.00 (+0.00%) ▲|SPG206.31-0.68 (-0.33%) ▼|T21.98-1.45 (-6.17%) ▼|TMO702.36+14.99 (+2.18%) ▲|TMUS153.32-4.44 (-2.81%) ▼|TSLA386.40+12.69 (+3.40%) ▲|TXN286.26+8.48 (+3.05%) ▲|UBER68.18-0.76 (-1.10%) ▼|UNH416.31-2.96 (-0.70%) ▼|UNP289.75+2.14 (+0.74%) ▲|UPS99.61+1.09 (+1.10%) ▲|USB59.31+0.22 (+0.36%) ▲|V409.27+2.70 (+0.66%) ▲|VZ43.41-1.14 (-2.55%) ▼|WFC82.43+0.23 (+0.28%) ▲|WMT118.01+0.16 (+0.13%) ▲|XOM177.68-0.18 (-0.10%) ▼|
14.6 C
New York
Wednesday, October 21, 2026

Tag: food

newsFORsourcecompanycontentinformation1releasesmarket

SKYRIZI® (risankizumab-rzaa) Now FDA Approved for Pediatric Use in Psoriatic Disease

SKYRIZI (risankizumab-rzaa) is now approved for patients six years of age and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis Approval includes a...

Nordic Naturals Ultimate Omega Featured in New Erewhon Smoothie by J Balvin

Watsonville, CA, June 26, 2026 (GLOBE NEWSWIRE) -- Nordic Naturals, the #1 selling fish oil brand in the U.S.‡, today announced that its award-winning Ultimate Omega® is a featured ingredient in Erewhon's newly launched, limited-edition “Chimba de Smoothie by J Balvin.”

Bauducco® Opens Largest U.S. Manufacturing Facility in Zephyrhills, Florida, Bringing 75 Years of Brazilian Baking Craftsmanship to American Tables

The iconic Brazilian brand -- beloved for its cookies, wafers, and specialty baked goods -- makes a landmark U.S. investment, deepening its commitment to...

Various Salem Foods brand Ground Spices and Spice Blends recalled due to undeclared wheat, sesame and mustard

OTTAWA, ON, June 26, 2026 /CNW/ - Product: Ground Spices and Spice Blends Issue: Food - Allergen - Wheat Food - Allergen - Sesame seeds...

Monopar Presents New Analyses of Phase 3 FoCus Data at EAN 2026 Showing Greater Neurologic and Global Clinical Benefit with ALXN1840 Versus Standard of...

WILMETTE, Ill., June 26, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced that new analyses from the Phase 3 FoCus randomized controlled clinical trial of ALXN1840 (tiomolibdate choline, TMC) will be presented at the 12th Congress of the European Academy of Neurology (EAN 2026), June 27–30, 2026, in Geneva, Switzerland. These analyses build upon the previously reported Phase 3 FoCus results demonstrating ALXN1840 met its primary endpoint of superior copper mobilization versus standard of care.

Lantheus Receives Complete Response Letter from FDA for LNTH-2501 (Ga 68 edotreotide)

BEDFORD, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding its New Drug Application (NDA) for LNTH-2501 (Gallium 68 edotreotide), a PET diagnostic imaging kit targeting somatostatin receptor-positive (SSTR+) neuroendocrine tumors (NETs). 

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Sobi receives complete response letter from FDA for NASP (nanoencapsulated sirolimus plus pegadricase)

STOCKHOLM, June 26, 2026 /PRNewswire/ --The FDA has requested additional data related to chemistry, manufacturing, and controls (CMC) and contract manufacturing facilities; no clinical...

Siren Biotechnology Awarded $8M in Non-Dilutive Grant Funding from the California Institute for Regenerative Medicine (CIRM) to Support Clinical Development of SRN-101 in High-Grade...

Siren Biotechnology awarded $8M in grant funding from the California Institute for Regenerative Medicine (CIRM) to support clinical development of SRN-101

The 34th Annual Giant BBQ Battle Hits Washington D.C. This Weekend, Bigger, Bolder, and Tastier Than Ever

Tito Puente Jr., Rare Essence, E.U., and Reverend Peyton's Big Damn Band headline an all-star musical lineup alongside champion pitmasters and culinary stars, including...

Minister Anandasangaree highlights launch of National Food Security Strategy

SCARBOROUGH, ON, June 26, 2026 /CNW/ - The Government of Canada is focused on building a stronger economy and making life more affordable for...

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Cosmos Health Signs Distribution Agreement With IMC, Owner of Qatar’s Largest Pharmacy Chain; Secures Initial Purchase Order of 31,000 Sky Premium Life Units

Cosmos Health signs distribution agreement with IMC, owner of Qatar's largest pharmacy chain. Secures purchase order of 31,000 Sky Premium Life units.

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsFood

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers